CD8A and acute myeloid leukemia: To specifically target CD123 on AML, we utilized a CAR construct that contains a scFv derived from a murine hybridoma, a CD8 hinge and transmembrane domain, and a cytoplasmic tail composed of 4-1BB co-stimulatory domain and CD3zeta signaling domain.